alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with naloxone in 3 studies
| Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (naloxone) | Trials (naloxone) | Recent Studies (post-2010) (naloxone) |
|---|---|---|---|---|---|
| 90 | 1 | 2 | 20,134 | 1,257 | 3,321 |
| Protein | Taxonomy | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50) | naloxone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.043 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0219 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0397 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1896 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.05 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0795 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0154 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0089 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.0055 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, BG; Kimes, AS; London, ED; Scheffel, U; Wilson, AA | 1 |
| Bush, LG; Gibb, JW; Hanson, GR; Midgley, LP | 1 |
| Hall, FS; Kitanaka, J; Kitanaka, N; Nishiyama, N; Takemura, M; Tanaka, K; Uhl, GR | 1 |
3 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and naloxone
| Article | Year |
|---|---|
Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
Topics: Animals; Autoradiography; Binding Sites; Binding, Competitive; Brain; Guanidines; Guinea Pigs; Iodobenzenes; Male; Mice; Receptors, sigma; Tissue Distribution | 1992 |
Characterization of phencyclidine-induced effects on neuropeptide Y systems in the rat caudate-putamen.
Topics: 4-Aminobutyrate Transaminase; Adrenergic beta-Antagonists; Aminocaproates; Aminooxyacetic Acid; Animals; Benzazepines; Carbazoles; Corpus Striatum; Dioxanes; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Administration Schedule; Idazoxan; Male; Naloxone; Neuropeptide Y; Phencyclidine; Prazosin; Psychotropic Drugs; Putamen; Pyrimidines; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Time Factors; Vigabatrin | 1992 |
Straub tail reaction in mice treated with σ(1) receptor antagonist in combination with methamphetamine.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Male; Methamphetamine; Mice; Mice, Inbred Strains; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Phenazocine; Pyrimidines; Receptors, Opioid, delta; Reflex; Tail; Time Factors | 2012 |